{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:33:32Z","timestamp":1793223212708,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10620-020-06439-4","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T09:25:14Z","timestamp":1593681914000},"page":"2005-2013","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Comorbid Diabetes in Inflammatory Bowel Disease Predicts Adverse Disease-Related Outcomes and Infectious Complications"],"prefix":"10.1007","volume":"66","author":[{"given":"Anand","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Teslova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4581-2267","authenticated-orcid":false,"given":"Dana J.","family":"Lukin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"key":"6439_CR1","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJM199110033251406","volume":"325","author":"DK Podolsky","year":"1991","unstructured":"Podolsky DK. Inflammatory bowel disease. N Engl J Med. 1991;325:1008\u20131016. https:\/\/doi.org\/10.1056\/NEJM199110033251406.","journal-title":"N Engl J Med"},{"key":"6439_CR2","first-page":"704","volume":"12","author":"EV Loftus Jr","year":"2016","unstructured":"Loftus EV Jr. Update on the incidence and prevalence of inflammatory bowel disease in the United States. Gastroenterol Hepatol (N Y). 2016;12:704\u2013707.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"6439_CR3","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.15585\/mmwr.mm6542a3","volume":"65","author":"JM Dahlhamer","year":"2016","unstructured":"Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of inflammatory bowel disease among adults aged\u2009\u226518\u00a0years\u2013United States, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:1166\u20131169. https:\/\/doi.org\/10.15585\/mmwr.mm6542a3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"6439_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4110\/in.2017.17.1.25","volume":"17","author":"DH Kim","year":"2017","unstructured":"Kim DH, Cheon JH. Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune Netw. 2017;17:25\u201340. https:\/\/doi.org\/10.4110\/in.2017.17.1.25.","journal-title":"Immune Netw"},{"key":"6439_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens8030126","author":"I Khan","year":"2019","unstructured":"Khan I, Ullah N, Zha L, et al. Alteration of gut microbiota in inflammatory bowel disease (IBD): Cause or consequence? IBD treatment targeting the gut microbiome. Pathogens. 2019;. https:\/\/doi.org\/10.3390\/pathogens8030126.","journal-title":"Pathogens"},{"key":"6439_CR6","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA. 2020. https:\/\/www.cdc.gov\/diabetes\/data\/statistics\/statistics-report.html."},{"key":"6439_CR7","doi-asserted-by":"publisher","first-page":"17016","DOI":"10.1038\/nrdp.2017.16","volume":"3","author":"A Katsarou","year":"2017","unstructured":"Katsarou A, Gudbjornsdottir S, Rawshani A, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016. https:\/\/doi.org\/10.1038\/nrdp.2017.16.","journal-title":"Nat Rev Dis Primers"},{"key":"6439_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11938-018-0188-9","volume":"16","author":"A Afzali","year":"2018","unstructured":"Afzali A, Katz S. Inflammatory bowel disease in the baby to baby boomer: pediatric and elderly onset of IBD. Curr Treat Options Gastroenterol. 2018;16:289\u2013305. https:\/\/doi.org\/10.1007\/s11938-018-0188-9.","journal-title":"Curr Treat Options Gastroenterol"},{"key":"6439_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature11450","volume":"490","author":"J Qin","year":"2012","unstructured":"Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55\u201360. https:\/\/doi.org\/10.1038\/nature11450.","journal-title":"Nature"},{"key":"6439_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000345107","volume":"59","author":"S Knapp","year":"2013","unstructured":"Knapp S. Diabetes and infection: is there a link? A mini-review. Gerontology. 2013;59:99\u2013104. https:\/\/doi.org\/10.1159\/000345107.","journal-title":"Gerontology"},{"key":"6439_CR11","doi-asserted-by":"publisher","first-page":"e000336","DOI":"10.1136\/bmjdrc-2016-000336","volume":"5","author":"W Abu-Ashour","year":"2017","unstructured":"Abu-Ashour W, Twells L, Valcour J, et al. The association between diabetes mellitus and incident infections: a systematic review and meta-analysis of observational studies. BMJ Open Diabetes Res Care. 2017;5:e000336. https:\/\/doi.org\/10.1136\/bmjdrc-2016-000336.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"6439_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1177\/1060028018754896","volume":"52","author":"SM McConachie","year":"2018","unstructured":"McConachie SM, Wilhelm SM, Bhargava A, Kale-Pradhan PB. Biologic-induced infections in inflammatory bowel disease: the TNF-alpha antagonists. Ann Pharmacother. 2018;52:571\u2013579. https:\/\/doi.org\/10.1177\/1060028018754896.","journal-title":"Ann Pharmacother"},{"key":"6439_CR13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/apt.13195","volume":"41","author":"AN Ananthakrishnan","year":"2015","unstructured":"Ananthakrishnan AN, Cagan A, Cai T, et al. Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015;41:1141\u20131148. https:\/\/doi.org\/10.1111\/apt.13195.","journal-title":"Aliment Pharmacol Ther"},{"key":"6439_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/DCR.0000000000000550","volume":"59","author":"A Bhakta","year":"2016","unstructured":"Bhakta A, Tafen M, Glotzer O, et al. Increased incidence of surgical site infection in IBD patients. Dis Colon Rectum. 2016;59:316\u2013322. https:\/\/doi.org\/10.1097\/DCR.0000000000000550.","journal-title":"Dis Colon Rectum"},{"key":"6439_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/000313481207800442","volume":"78","author":"BA Coakley","year":"2012","unstructured":"Coakley BA, Divino CM. Identifying factors predictive of surgical-site infections after colectomy for fulminant ulcerative colitis. Am Surg. 2012;78:481\u2013484.","journal-title":"Am Surg"},{"key":"6439_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12664-018-0855-8","volume":"37","author":"A Kumar","year":"2018","unstructured":"Kumar A, Kim M, Lukin DJ. Helicobacter pylori is associated with increased risk of serrated colonic polyps: analysis of serrated polyp risk factors. Indian J Gastroenterol. 2018;37:235\u2013242. https:\/\/doi.org\/10.1007\/s12664-018-0855-8.","journal-title":"Indian J Gastroenterol"},{"key":"6439_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jcrc.2017.03.027","volume":"40","author":"IMB Francischetti","year":"2017","unstructured":"Francischetti IMB, Szymanski J, Rodriguez D, Heo M, Wolgast LR. Laboratory and clinical predictors of 30-day survival for patients on extracorporeal membrane oxygenation (ECMO): 8-year experience at Albert Einstein College of Medicine, Montefiore Medical Center. J Crit Care. 2017;40:136\u2013144. https:\/\/doi.org\/10.1016\/j.jcrc.2017.03.027.","journal-title":"J Crit Care"},{"key":"6439_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"key":"6439_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1365-2036.2011.04915.x","volume":"35","author":"JW Harper","year":"2012","unstructured":"Harper JW, Welch MP, Sinanan MN, Wahbeh GT, Lee SD. Co-morbid diabetes in patients with Crohn\u2019s disease predicts a greater need for surgical intervention. Aliment Pharmacol Ther. 2012;35:126\u2013132. https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04915.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"6439_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.7150\/jca.14264","volume":"7","author":"JK Choi","year":"2016","unstructured":"Choi JK, Kim DW, Shin SY, Park EC, Kang JG. Effect of ulcerative colitis on incidence of colorectal cancer: results from the nationwide population-based cohort study (2003\u20132013). J Cancer. 2016;7:681\u2013686. https:\/\/doi.org\/10.7150\/jca.14264.","journal-title":"J Cancer"},{"key":"6439_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000380763","volume":"91","author":"PS Fitzmorris","year":"2015","unstructured":"Fitzmorris PS, Colantonio LD, Torrazza Perez E, Smith I, Kakati DD, Malik TA. Impact of metabolic syndrome on the hospitalization rate of Crohn\u2019s disease patients seen at a tertiary care center: a retrospective cohort study. Digestion. 2015;91:257\u2013262. https:\/\/doi.org\/10.1159\/000380763.","journal-title":"Digestion"},{"key":"6439_CR22","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1097\/MIB.0000000000000763","volume":"22","author":"B Click","year":"2016","unstructured":"Click B, Ramos Rivers C, Koutroubakis IE, et al. Demographic and clinical predictors of high healthcare use in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1442\u20131449. https:\/\/doi.org\/10.1097\/MIB.0000000000000763.","journal-title":"Inflamm Bowel Dis"},{"key":"6439_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/1474651413495703","volume":"13","author":"C Nwaneri","year":"2013","unstructured":"Nwaneri C, Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. Br J Diabetes Vasc Dis. 2013;13:192\u2013207. https:\/\/doi.org\/10.1177\/1474651413495703.","journal-title":"Br J Diabetes Vasc Dis"},{"key":"6439_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/MIB.0b013e31827f27ae","volume":"19","author":"M Bewtra","year":"2013","unstructured":"Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohn\u2019s disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis. 2013;19:599\u2013613. https:\/\/doi.org\/10.1097\/MIB.0b013e31827f27ae.","journal-title":"Inflamm Bowel Dis"},{"key":"6439_CR25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cgh.2006.12.027","volume":"5","author":"JF Rodemann","year":"2007","unstructured":"Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:339\u2013344. https:\/\/doi.org\/10.1016\/j.cgh.2006.12.027.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6439_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjy143","volume":"13","author":"B Balram","year":"2019","unstructured":"Balram B, Battat R, Al-Khoury A, et al. Risk factors associated with Clostridium difficile infection in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2019;13:27\u201338. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy143.","journal-title":"J Crohns Colitis"},{"key":"6439_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2337\/dc17-2131","volume":"41","author":"IM Carey","year":"2018","unstructured":"Carey IM, Critchley JA, DeWilde S, Harris T, Hosking FJ, Cook DG. Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study. Diabetes Care. 2018;41:513\u2013521. https:\/\/doi.org\/10.2337\/dc17-2131.","journal-title":"Diabetes Care"},{"key":"6439_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/MIB.0000000000001049","volume":"23","author":"ED Shah","year":"2017","unstructured":"Shah ED, Farida JP, Siegel CA, Chong K, Melmed GY. Risk for overall infection with anti-TNF and anti-integrin agents used in IBD: a systematic review and meta-analysis. Inflamm Bowel Dis. 2017;23:570\u2013577. https:\/\/doi.org\/10.1097\/MIB.0000000000001049.","journal-title":"Inflamm Bowel Dis"},{"key":"6439_CR29","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.3748\/wjg.v25.i18.2240","volume":"25","author":"SS Gong","year":"2019","unstructured":"Gong SS, Fan YH, Han QQ, Lv B, Xu Y. Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease. World J Gastroenterol. 2019;25:2240\u20132250. https:\/\/doi.org\/10.3748\/wjg.v25.i18.2240.","journal-title":"World J Gastroenterol"},{"key":"6439_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz305","author":"H Din","year":"2020","unstructured":"Din H, Anderson AJ, Ramos Rivers C, et al. Disease characteristics and severity in patients with inflammatory bowel disease with coexistent diabetes mellitus. Inflamm Bowel Dis. 2020;. https:\/\/doi.org\/10.1093\/ibd\/izz305.","journal-title":"Inflamm Bowel Dis"},{"key":"6439_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.diabet.2011.11.006","volume":"38","author":"MC Calle","year":"2012","unstructured":"Calle MC, Fernandez ML. Inflammation and type 2 diabetes. Diabetes Metab. 2012;38:183\u2013191. https:\/\/doi.org\/10.1016\/j.diabet.2011.11.006.","journal-title":"Diabetes Metab"},{"key":"6439_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bbacli.2015.11.002","volume":"5","author":"A Jurjus","year":"2016","unstructured":"Jurjus A, Eid A, Al Kattar S, et al. Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: the links. BBA Clin. 2016;5:16\u201324. https:\/\/doi.org\/10.1016\/j.bbacli.2015.11.002.","journal-title":"BBA Clin"},{"key":"6439_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12328-017-0813-5","volume":"11","author":"A Nishida","year":"2018","unstructured":"Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11:1\u201310. https:\/\/doi.org\/10.1007\/s12328-017-0813-5.","journal-title":"Clin J Gastroenterol"},{"key":"6439_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/MEG.0000000000001648","volume":"32","author":"A Kumar","year":"2020","unstructured":"Kumar A, Lukin DJ. Incident heart failure is a predictor of adverse outcomes in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2020;32:205\u2013215. https:\/\/doi.org\/10.1097\/MEG.0000000000001648.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06439-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-020-06439-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06439-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T23:28:01Z","timestamp":1625182081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-020-06439-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["6439"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06439-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,2]]},"assertion":[{"value":"31 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Anand Kumar, Tatiana Teslova, and Erin Taub have no financial interests to disclose. Joshua D. Miller has received consulting fees from Joslin Diabetes Center. Dana J. Lukin has received consulting fees from Abbvie, Abgenomics, Pfizer, Prometheus, and Takeda and Grant Support from Abbvie, Kenneth Rainin Foundation, and Takeda. The authors have no non-financial competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}